It is relevant to discuss hypertriglyceridemia when LDL-c and inflammation are well-controlled? Prof. Stroes discusses the association of triglycerides and triglycerde-rich lipoproteins with CV risk.
Trials with colchicine included different CVD patients; post-MI or with chronic coronary disease. Tjerk Opstal and colleagues investigated whether the efficacy of colchicine was dependent of the time to previous ACS event.
Treatment with the PCSK9 inhibitor evolocumab in high CV risk patients reduced the risk of acute arterial events across all vascular territories, as shown in a post hoc analysis of FOURIER.
Which formulation of omega-3 PUFAs should be used, and to whom and when should omega-3 PUFAs be prescribed? Prof. Lale Tokgözoğlu provides an overview of trials with omega-3 PUFAs and CV outcomes.
Prof. Peter Libby brings us up to date on some novel aspects of inflammation in atherosclerosis.
EASD 2021 Cardiac adipose tissue measured by CT was reduced by treatment with liraglutide compared to placebo in patients with T2DM, but this reduction was dependent on changes in weight loss.
EASD 2021 This secondary analysis of the DAPA-CKD trial showed that the efficacy and safety of dapagliflozin on kidney and CV outcomes was consistent across subgroups of baseline albuminuria in patients with CKD, with and without T2DM.
Prof. Coats discusses the dilemma when hyperkalemia occurs in HF patients: discontinuation/reducing RAASi and lose the benefits of RAASi vs. continued RAASi and accept the presence of hyperkalemia.
EASD 2021 Using data of four semaglutide trials, this exploratory analysis showed that both subcutaneous and oral semaglutide reduced high-sensitivity CRP in patients with T2DM.
EASD 2021 There is a wide distribution of 10-year and lifetime CV risk in diabetes patients with and without a history of CVD. Use of SGLT2 inhibitors and GLP-1RAs was low in all groups.
The new therapeutic options for LDL-c lowering, bempedoic acid and inclisiran, are discussed by prof. Ballantyne. How do these drugs lower LDL-c and what are the findings in phase III programs?
EASD 2021 HbA1c, body weight and SBP were lowered by semaglutide and liraglutide, regardless of background SGLT2i therapy in diabetes patients, in a post hoc analysis of SUSTAIN 6.